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Abstract 
 
Background: The evidence for the possibilities of conditioned endocrine placebo effects is 
growing. However, the conditioned placebo effect of oxytocin has not yet been researched. 
Also, research suggests that psychological factors, such as anxiety and stress may influence 
placebo responses. We examined if it is possible to induce a conditioned placebo response in 
oxytocin and whether this response is influenced by anxiety and stress. 
Methods: In a two-phase conditioning paradigm, 66 women (age: 18-33) were randomly 
allocated to a conditioned group or to a control group. In the first phase (acquisition phase), 
participants in the conditioned group received oxytocin nasal spray together with a distinctive 
smell (conditioned stimulus: CS). Whereas, participants in the control group received a 
placebo together with the CS. In the second phase (evocation phase), both groups received a 
placebo in combination with the CS. Salivary oxytocin levels were measured several times 
throughout both phases. Questionnaires were used to measure levels of anxiety (State-Trait 
Anxiety Inventory) and stress (Special Events Questionnaire II).  
Results: The results of a repeated measures ANCOVA indicated that there was a significant 
difference in salivary oxytocin levels between conditioned and control group in the evocation 
phase (F(1,61) = 7.45, p = .008). Multiple regression analysis (MRA) indicated that anxiety 
did not moderate the effects of conditioning on oxytocin release (b = 1.57, p = .609). 
Nevertheless, MRA indicated that stress moderated the effects of the conditioned placebo 
effect of oxytocin (b = .39, p = .038).  
Conclusion: Our results indicate that it is possible to induce a placebo effect in oxytocin 
through the mechanism of classical conditioning. Furthermore, participants with higher stress 
levels demonstrated a higher placebo effect. These results indicate that stress positively 
affects the conditioned placebo response in oxytocin.  
Keywords: Placebo effect, Oxytocin, Classical conditioning, Anxiety, Stress 
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1. Introduction 
 
 Placebo effects are genuine positive psychophysiological outcomes of a treatment that 
are attributable to individual treatment expectations and psychosocial context, rather than the 
action of medications or interventions (Colloca, 2018). According to Gaab et al. (2018), 
placebos should be understood as a principle rather than a distinct and singular procedure, 
because placebos come in various forms and shapes. For instance, they can encompass inert 
substances, such as the classical sugar pill (Gaab, Kossowsky, Ehlert, & Locher, 2019). They 
can also encompass surgical procedures and acupuncture needles. Jonas et al. (2015) 
researched placebo effects of surgical procedures in a meta-analysis, in which randomized 
controlled trials of surgical procedures were included. These were either real surgery 
procedures or sham surgical procedures for comparison. The observed outcome changes in the 
sham groups, also referred to as placebo responses, were generally large. In conclusion, the 
sham surgical procedures were also effective. Kaptchuck et al. (2006), researched the placebo 
effects of a sham acupuncture needle in a randomized controlled trial in patients with 
persistent arm pain. The sham acupuncture needle had an effect on self reported pain and 
severity of symptoms, thus a placebo response occurred. The above described examples are 
only a few manners of the application of placebos, the possibilities are very broad.  
Moreover, there are also various psychological mechanisms trough which placebo 
responses can be elicited. The most well researched mechanisms are the mechanism of 
expectations and the learning mechanism of classical conditioning. Benedetti et al. (2003), 
suggested that placebo responses can be induced by expectations when conscious 
physiological processes are involved, whereas placebo responses can be induced by classical 
conditioning when unconscious physiological functions come into play. Expectations, with 
regards to placebo responses, are conscious events whereby the patient expects a certain 
benefit (Benedetti & Piedimonte, 2019). The general idea is that thoughts and beliefs about 
outcome expectations may have positive effects on a certain outcome. In clinical trials, 
expectations are often induced by verbal suggestion. When this is the case, verbal information 
is conveyed which may influence the expectations someone has (Benedetti, Mayberg, Wager, 
Stohler, & Zubieta, 2005; Enck, Benedetti, & Schedlowski, 2008). Placebo effects induced by 
positive verbal suggestion are extensively studied in pain research. For instance in the study 
of Skvortsova et al. (2018), in which there were two groups of participants. The first group 
was an experimental group that received positive verbal suggestions about the active 
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substance in a nasal spray. The positive suggestion contained the message that previous 
studies have demonstrated that the active substance in the spray decreased pain sensitivity. 
The researchers also told participants in this group that it was expected for them to feel less 
pain during a pain task after the administration of the spray. The other group was a control 
group and did not receive any verbal suggestions about the active substance in the nasal spray. 
In this study, positive verbal suggestion successfully elicited placebo analgesia.  
 Classical conditioning is a process that begins with an unconditioned stimulus (US) 
and a neutral stimulus (NS). The US evokes a certain natural response, which is called the 
unconditioned response (UR), the NS doesn’t evoke this response. During the process the NS 
and the US are paired repeatedly. Eventually, the NS alone also evokes the UR. The NS has 
become a conditioned stimulus (CS) and the response it evokes is called a conditioned 
response (CR). In experiments the first conditioning phase is called acquisition, this is the 
pairing phase, where the NS becomes a CS. After the acquisition phase, experiments 
generally move on to the evocation phase. This is the testing phase, wherein the CS is 
presented alone. It is measured whether a CR is elicited or not by presenting the CS alone 
(Colloca & Miller, 2011; Tekampe et al., 2018). Colloca and Miller (2011) described the 
conditioned placebo effect as a response to an index sign (CS) through which the individual 
learns to experience a favorable outcome.  
Some factors can influence the conditioned placebo response, for example 
psychological factors such as anxiety and stress. Anxiety is a psychological construct that is 
characterized by feelings of tension, worried thoughts and physical changes, such as an 
increased blood pressure (Kazdin, 2000). Stress is a psychological state that is characterized 
by feelings of pressure and physical arousal. Different systems in the human body are 
activated by stress, such as the sympathetic nervous system (SNS) and the hypothalamic 
pituitary adrenal axis (HPA-axis). These systems regulate different processes in the body, for 
example: blood pressure, heart rate and the release of certain stress hormones (e.g. cortisol 
and adrenaline) (Butler, 1993; Harris, 2020). Vase, Robinson, Verne, and Price (2005) 
suggested that a reduction in anxiety may be enhancing the placebo effect. In their study to 
analgesic placebo effects in patients with irritable bowel syndrome, they found that the 
decrease of anxiety levels was associated with an increase of the analgesic placebo effect. 
Similar effects were found in stress, a study of Benedetti, Amanzio, Vighetti, and Asteggiano 
(2006) showed that a reduction of stress was associated with an enhanced analgesic placebo 
response (Flaten, Aslaksen, Lyby, & Bjorkedal, 2011). However, little research has yet been 
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done on the influence of these factors on placebo responses. Thus far, the effects of anxiety 
and stress on placebo responses have only been studied in research on analgesia. 
Placebo responses are found in different systems in the human body, including the 
endocrine system (Skvortsova et al., 2019). The main mechanism through which placebo 
responses in the endocrine system can be induced is classical conditioning. One study 
examined if hormonal placebo responses can be induced through the mechanism of (verbally 
induced) expectations, but it did not find an effect (Benedetti et al., 2003). During hormonal 
conditioning, in the acquisition phase, the hormone is presented in combination with a NS. 
This could be a distinctive smell for example. In the acquisition phase, an association between 
the hormone and the NS needs to be formed. The acquisition phase is over, when the NS 
became a CS. In the evocation phase, the hormone is replaced with a placebo and presented in 
combination with the CS. If a hormone is conditioned as described here, an increase of the 
hormone (CR) should be elicited when presenting the CS alone. Examples of hormones that 
are proven possible to condition are cortisol, growth hormone and insulin (Benedetti et al., 
2003; Johansen, Brox, & Flaten, 2003; Sabbioni et al., 1997; Stockhorst, de Fries, 
Steingrueber, & Scherbaum, 2011; Stockhorst et al., 2004). In the study of Stockhorst et al. 
(2011) insulin was conditioned using insulin as a US and a tarry smell (meta-cresol) as a CS. 
The expected CR to the CS was an increase in insulin, which happened in the evocation phase 
of this study. Thus, insulin was successfully conditioned here. The current study is the first 
study that is looking at the possibility of conditioning the hormone oxytocin in humans. The 
study of Onaka and Yagi (1998) showed that oxytocin can be successfully conditioned in rats. 
However, this effect extinguished over time when not reinforced.  
Oxytocin is a hormone that is produced in the hypothalamus. From here, it transports 
to the pituitary gland, where oxytocin is stored and secreted (Meyer-Lindenberg, Domes, 
Kirsch, & Heinrichs, 2011). Oxytocin has effects on maternal behavior: it stimulates uterine 
contractions during labor and lactation during breast feeding (Veening, de Jong, Waldinger, 
Korte, & Olivier, 2015). Also, it improves the mother-child bond (Feldman, 2012). More 
examples of social behaviors in which oxytocin is involved are: facilitating approach behavior 
and increasing trust (Churchland & Winkielman, 2012; Yan, Yong, Huang, & Ma, 2018). 
Other positive effects of oxytocin are: increasing how attractive we find others and reducing 
pain sensitivity (Rash, Aguirre-Camacho, & Campbell, 2014; Theodoridou, Rowe, Penton-
Voak, & Rogers, 2009). 
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 There are several studies that have investigated possible implications of oxytocin 
treatment in clinical practice. For example, Bertsch et al. (2013) found that oxytocin may 
decrease social threat hypersensitivity in patients with borderline personality disorder. In 
response to decreasing threat hypersensitivity, anger and aggressive behavior may be 
decreased in these patients. Also, there is tentative evidence that treatment with oxytocin has 
improving effects on aspects of social cognition and emotional well-being in individuals with 
autism spectrum disorder (Anagnostou et al., 2012). Moreover, treatment with oxytocin might 
improve glucose homeostasis, increase insulin sensitivity and may lead to weight loss in 
overweight adults (Lawson, 2017). However, it is important to note that the exact implications 
of oxytocin in clinical practice still need further investigation.  
More evident results exist in research of the clinical possibilities on the formation of 
placebo responses via classical conditioning. For instance, research has demonstrated that 
placebos can alleviate certain symptoms, such as symptoms of pain, depression and 
Parkinson’s disease (Evers et al., 2018; Forsberg, Martinussen, & Flaten, 2017; Kaptchuk & 
Miller, 2015). Also, placebos could be useful in pharmacological treatments through the 
implementation of placebo-controlled dose reduction. This is a procedure in which a certain 
amount of pharmacological treatment is replaced by a placebo while maintaining the efficacy 
of the treatment (Doering & Rief, 2012). Previous research has demonstrated that this is 
possible in children with ADHD. In this research placebos were paired with stimulant 
medication which elicited a placebo response. This response allowed children with ADHD to 
effectively be treated on half of their optimal stimulant dose (Sandler, Glesne, & Bodfish, 
2010). Placebo-controlled dose reduction also has the potential to alleviate side effects while 
preserving therapeutic benefits or to reduce health care costs (Doering & Rief, 2012; 
Tekampe et al., 2018). Lastly, conditioned placebo responses has the potential to be useful as 
a supporting treatment without increasing the medication dose. This has been demonstrated in 
a study to immunosuppressive medications in renal transplant patients. In this study, the 
effects of the medications increased even though the medication dose remained the same 
(Kirchhof et al., 2018). 
Considering the possibilities of placebo treatment via classical conditioning and the 
tentative possibilities of oxytocin treatment, classical conditioning of oxytocin might be 
promising. The potential to condition oxytocin release would open additional perspectives for 
oxytocin treatment in clinical practice. Therefore, it is relevant to elucidate possible factors 
that may influence the classically conditioned placebo response of oxytocin. As previously 
mentioned, anxiety and stress may influence placebo responses (Benedetti et al., 2006; Flaten 
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et al., 2011; Vase et al., 2005). However, possible effects of anxiety and stress on the placebo 
response of oxytocin have not yet been researched.  
The current study investigates the classical conditioning of oxytocin. This study has 
two aims. The first aim is to investigate if it is possible to induce a placebo response in 
oxytocin through classical conditioning. We hypothesized that after repeated pairings of 
oxytocin with a neutral stimulus in the acquisition phase, the neutral stimulus becomes a 
conditioned stimulus and will trigger a conditioned response in the beginning of the evocation 
phase. The unconditioned response to the administration of exogenous oxytocin (US) triggers 
further (endogenous) oxytocin release by so-called feed-forward mechanisms (van 
Ijzendoorn, Bhandari, van der Veen, Grewen, & Bakermans-Kranenburg, 2012). Therefore, in 
this case, the conditioned response would be elicited when an increase in oxytocin levels is 
evoked in response to the conditioned stimulus. The second aim is to investigate if anxiety 
and stress influence placebo responses of oxytocin. Hypothesized is that after having 
experienced more anxiety or stress, participants will show reduced levels of classically 
conditioned endogenous oxytocin levels compared to participants who show less anxiety or 
stress. 
2. Methods 
2.1 Study Design 
 The study was a two-phase randomized controlled trial, it is presented in Figure 1. The 
study started with a screening session. After the screening session, participants were randomly 
assigned to one of two groups: a conditioned group or a control group. The first phase was 
called the acquisition phase. In this phase the odor of rosewood aroma oil (conditioned 
stimulus, CS) was presented together with the administration of oxytocin in the conditioned 
group. In the control group, the CS was presented together with the administration of a 
placebo. The second phase was called the evocation phase. This phase started four days after 
the last day of the acquisition phase, thus starting on the same day of the week as the 
acquisition phase. Participants in the conditioned and control groups were given the placebo 
in combination with the CS during three consecutive days. The study had a double blind 
design, both the participants and the researchers did not know if participants would receive 
oxytocin or a placebo in the acquisition session. 
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Note. Abbreviation: STAI-S is State-Trait Anxiety Inventory 
Figure 1. Study Design 
2.2 Participants 
Participants in the study were 66 healthy women (N conditioned group = 33, N control 
group = 33) between the age of 18 and 33, who use oral contraceptives. The reason for only 
including women who use oral contraceptives, is that they have stable oxytocin levels 
throughout the menstrual cycle (Salonia et al., 2005). They were asked to participate through 
means of flyers spread at Leiden University. Exclusion criteria were serious neurological or 
psychiatric disorders, substance abuse, (intended) pregnancy or known hypervigilance to one 
of the ingredients of the oxytocin spray or the odor.  
2.3 Procedure 
 Participants were asked to come to the laboratory for the screening, the acquisition 
phase and for the evocation phase. The entire experiment took place at a laboratory of the 
Social Science department of Leiden University. 
At the screening, exclusion criteria were checked, then participants were asked to fill 
in the Special Events Questionnaire II. Also, saliva samples were taken to determine baseline 
levels of oxytocin.  
+ 5 min 
    Saliva sample 
1 minute Rosewood 
aroma oil odor 
Placebo                 
spray 
1 minute Rosewood 
aroma oil odor 
Screening session 
- Exclusion criteria check 
- Special Events Questionnaire II 
- Baseline oxytocin levels 
Acquisition sessions (Day 1-3) 
3. Evocation session 
    1 minute Rosewood 
aroma oil odor 
Evocation sessions (Day 4-5) 
Evocation session (Day 6) 
     Placebo/Oxytocin 
spray 
1 minute Rosewood               
aroma oil odor 
Baseline 
Saliva sample 
+ 50 min 
    Saliva sample 
+ 20 min 
     Saliva sample 
+ 5 min 
    Saliva sample 
1 minute Rosewood 
aroma oil odor 
Placebo                 
spray 
1 minute Rosewood 
aroma oil odor 
Baseline      
Saliva sample 
STAI-S 
Baseline 
Saliva sample 
STAI-S 
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The acquisition phase lasted three consecutive days. During the acquisition sessions, 
participants received a nasal spray either with 24 international units of oxytocin or with the 
placebo, coupled with the odor of rosewood aroma oil. The placebo was a nasal spray, which 
was identically looking and smelling to the oxytocin nasal spray, only without oxytocin in it. 
First a baseline saliva sample was taken, to measure oxytocin levels. After this, participants 
were asked to breathe normally through nasal goggles for one minute before and one minute 
after the spray administration, to smell the rosewood aroma oil.  
The evocation phase also lasted three consecutive days. In this phase, participants 
were first asked to fill in the State-Trait Anxiety Inventory (STAI-S) during each session. 
After this, participants in both the conditioned and control group received placebo spray in 
combination with rosewood aroma oil odor. Saliva samples were taken four times (baseline, 
5, 20 and 50 minutes after the placebo administration) to measure oxytocin levels.  
2.4 Questionnaires  
To measure baseline state anxiety, the STAI-S (α = .82) was used. State anxiety entails 
a person’s current levels of anxiety. This questionnaire consists of six items, which comprise 
of the following statements: ‘I feel calm’, ‘I am tense’, ‘I feel upset’, ‘I am relaxed’, ‘I feel 
content’, ‘I am worried’. Answers are given on a four-point Likert scale. The total score 
ranges from 6 to 24, with higher scores indicating more anxiety (Marteau & Bekker, 1992).  
To measure stress at baseline, a translated (into the Dutch language) and shorter 
version of The Negative Life Events and Trauma Questionnaire, called Special Events 
Questionnaire II, was used (Morgan & Janoffbulman, 1994; van Laarhoven et al., 2012). 
Participants were asked to indicate whether they recently experienced any of the stressful 
events given in a list. A few examples of stressful events given in this list are: the death of a 
parent, brother, sister or a partner and being involved in a serious accident. If any of these 
stressful events were experienced, participants were asked to rate this event on a scale of 0 
(the event was experienced as not stressful at all) to 100 (the event was experienced as 
extremely stressful). 
2.5 Statistical analyses 
The data analysis was performed using SPSS Statistics Version 25 (IBM Corporation). 
p-values were reported and considered significant at the < .05 level. Baseline characteristics 
between the conditioned and control group were compared using independent sample t-test. 
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Assumptions for performing independent samples t-test were checked. The t-test was robust 
for a possible violation of normality, because of large enough sample sizes (lowest N = 32) 
(Schmidt, 2018). The assumption of homogeneity was not violated for any of the variables.  
To test the first research question: if it is possible to induce a placebo response in 
oxytocin through classical conditioning, a between subject repeated measures analysis of 
covariance (ANCOVA) was carried out. Conditioned and control groups were compared on 
the three oxytocin measurements of the first evocation session (day 4) with the baseline 
oxytocin measurement of the same evocation session as a covariate. Thus, the three oxytocin 
measurements were the dependent variables and group was the independent variable. The 
reason for using the measurements of the first evocation session is that earlier research in rats 
showed that a placebo response of oxytocin reduces in a period of time when not reinforced 
(Onaka & Yagi, 1998). Therefore, in the current study, we expect a reduction in a possible 
placebo response over time as well. We expected the placebo response of oxytocin to be the 
highest in the first evocation session.  
Prior to performing the analysis, the assumptions for repeated measures ANCOVA 
were tested. The assumption of normality was tested using the Shapiro-Wilk test. The results 
of this test indicated a violation of normality on oxytocin scores for each group, except for the 
third measurement in the conditioned group (oxytocin 5 minutes after placebo administration, 
control group: W = .619, p < .001, conditioned group: W = .921, p = .022; oxytocin 20 
minutes after placebo administration, control group: W = .586, p < .001, conditioned group: W 
= .875, p = .002; oxytocin 50 minutes after placebo administration, control group: W = .648, p 
< .001, conditioned group: W = .951, p = .159). Log transformations on the oxytocin variables 
were performed to correct for this violation. Sphericity was measured with Mauchly’s test of 
sphericity. Mauchly’s test did not indicate any violation of sphericity (χ2(2) = 2.06, p = .358). 
Furthermore, assumptions for adding a covariate were tested, they include the assumption of 
linearity and the assumption of homogenous regression slopes. The assumption linearity was 
tested by analyzing plots of residuals against predicted values for all four oxytocin 
measurements (baseline, 5, 20 and 50 minutes after the placebo administration). No signs of 
non-linearity were found. Lastly, the assumption of homogeneity of regression slopes was 
tested by computing a separate repeated measures ANCOVA with covariate (baseline 
oxytocin measurement) times factor (oxytocin measurements 5, 20 and 50 minutes after 
placebo administration) interaction. The covariate times factor interaction was not significant 
(F(2,120) = .96, p = .386), so we assume homogenous regression slopes. Furthermore, the 
data were screened for outliers on dependent variables, using z-scores. Z-scores above 3 or 
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below -3, were considered to indicate outliers. When looking at standardized residuals of the 
dependent variables, the three oxytocin measurements of 5, 20, and 50 minutes after placebo 
administration, there were five outliers. One outlier was found on the oxytocin measurement 5 
minutes after placebo administration, with a z-score of 3.09. Two outliers were found on the 
oxytocin measurement 20 minutes after placebo administration, with z-scores of -3.33 and 
3.28. We did not remove these outliers from our data. They were no extreme outliers and 
removing them from our data would have affected the generalizability of our study.  
To test the second research question: if anxiety and stress influence placebo responses 
of oxytocin, two moderation analyses were carried out, one for anxiety and one for stress. The 
variable of anxiety was derived by adding up rated scores of state anxiety (STAI-S) and the 
variable of stress was derived by adding up rated scores of stressful life events (Special 
Events Questionnaire II). Moderation analyses were carried out in SPSS using linear multiple 
regression analyses, to investigate if there are main effects and/or interaction effects. A 
significant interaction effect would indicate moderation. In SPSS, we recoded conditioned and 
control group into dummy variables. The conditioned group was assigned to number 1 and the 
control group was assigned to 0. Also, we centered the continuous variables, these included 
the first salivary oxytocin measurement after placebo administration and both the anxiety and 
stress measurements. The last preparatory step we performed in SPSS, before performing the 
moderation analyses, was creating interaction terms of dummy group times centered anxiety 
and dummy group times centered stress. In both analyses, the first oxytocin measurement 
after placebo administration was the dependent variable. In the first moderation analysis, the 
independent variables were the dummy coded variable of group, centered anxiety and the 
interaction term of dummy coded group and centered anxiety. In the second analysis, the 
independent variables were the dummy coded variable of group, centered stress and the 
interaction term of dummy coded group and centered stress.  
Before carrying out the analyses, the assumptions of multiple regression analysis were 
tested. The assumption of linearity and the assumption of homoscedasticity were tested by 
analyzing a plot of residuals against predicted values of the dependent variable for both 
analyses. No systematic deviation from linearity and no signs of heteroscedasticity were 
found. The F-test in both analyses were robust for a possible violation of normality because of 
a large enough sample size (lowest N = 32). Furthermore, the data were screened for outliers 
on dependent variables, using z-scores. Z-scores above 3 or below -3, were considered to 
indicate outliers. When looking at standardized residuals of the dependent variable of the first 
analysis, there was one outlier, with a z-score of 5.46. In the second analysis, there were two 
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outliers, with z-scores of 3.07 and 4.63. We did not remove them from our data, because that 
would have affected the generalizability of the study.  
3. Results 
Baseline characteristics are presented in Table 1. Participants were between the age of 
19 and 33 and the mean age was 21.4 (SD = 2.4). No significant differences between 
participants in the conditioned and control group were found for age (t(64) = -.77, p = .443). 
Also, no significant differences between participants in the conditioned and control group 
were found for the STAI-S (t(64) = -.90, p = .370) measuring State Anxiety and for the 
Special Events Questionnaire II (t(64) = -.472, p = .638) measuring Stress. Furthermore, no 
significant differences between the conditioned and control group were found for the 
covariate, the baseline oxytocin measurement (t(63) = -1.24, p = .221). Two oxytocin samples 
were not analyzed due to clotting (one from a participant from the conditioned group and one 
from a participant from the control group). 
Table 1. Baseline Characteristics With Standard Deviations  
  
N 
 
Total 
M  ± SD 
 
Range 
 Group      
N Conditioned 
M  ± SD 
N Control 
M  ± SD 
t p 
(2-sided) 
Age 66 21.4 ± 2.4 18-33  33 21.2 ± 2.8 33 21.7 ± 1.9 -.77 .443 
Questionnaires           
State Anxiety 
(STAI-S) 
66 9.9 ± 2.7 6-17  33 9.6 ± 2.9 33 10.2 ± 2.6 -.90 .370 
Stress  
(Special Events 
Questionnaire II) 
 
66 31.7 ± 41.4 0-150  33 29.2 ± 38.3 33 34.1 ± 44.9 -.47 .638 
Covariate: 
Baseline oxytocin 
 
65 
 
14.2 ± 14.7 
 
1-113 
  
32 
 
11.9 ± 8.4 
 
33 
 
16.4 ± 18.3 
 
-1.24 
 
.221 
 
The results of the repeated measures ANCOVA are presented in Table 2 and Figure 2. 
They show that, after controlling for baseline levels, there was a significant difference 
between the conditioned and the control group, with a small to medium effect size (F(1,61) = 
7.45, p = .008, ηp
2 
= .109). The salivary oxytocin levels in the conditioned group (M = 1.18, 
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SD = .05) were higher in comparison to the control group (M = .99, SD = .05). There was no 
significant effect of time (F(2, 122) = .23, p = .798), the oxytocin levels did not significantly 
differ within participants between the three time measurements. The time x group interaction 
was also not significant (F(2,122) = 1.12, p = .330, ηp
2 
= .018).  
Note. Ncontrol = 32, Nconditioned = 32; the dependent variables of Time and the covariate were log 
transformed; Abbreviations: SS is sum of squares, MS is means squares. 
*bw5min = .65, bw20min = .64, bw50min = .51 
Figure 2. Mean group oxytocin scores by time of measurement, error bars indicate standard 
error  
 
 
Table 2. Results Repeated Measures ANCOVA 
Source df SS MS F p ηp
2
 
Between subjects       
Group 1 1.62 1.62 7.45 .008 .109 
Baseline*  1 5.97 5,97 27.49 < .001 .311 
Residuals 61 13.24 .22    
Within subjects       
Time 2 .02 .01 0.23 .798 .004 
Time x Baseline 2 .07 .03 0.88 .418 .014 
Time x Group 2 .09 .04 1.12 .330 .018 
Residuals 122 4.63 .04    
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The results of the moderation analyses are presented in Table 3, Table 4, Figure 3 and 
Figure 4. The model of anxiety with the interaction term (Table 3; Model 2 and Figure 3) was 
not significant (F(3,61) = 1.71, p = .174, R² = .078, R² = .004). This model predicted only 
7.8% of the variance in the sample and predicted only 0.4% more than the model without 
interaction term. The interaction effect between group and anxiety was not significant (b = 
1.57, p = .609). Non-significance of the interaction effect indicates that there is no moderation 
effect. Anxiety Model 1 only includes the main effects of group and anxiety (Table 3; Model 
1), this model is also not significant (F(2,62) = 2.74, p = .093, R² = .074). The main effect of 
group was the only significant effect in this model. (b = 17.54, p = .036). Given that the 
control group was coded as 0, the conditioned group as 1 and b = 17.54, the predicted mean 
value of the conditioned group is 17.54 units higher than the mean value of the control group. 
The main effect of anxiety was not significant (b = 1.19, p = .431). 
Note. N = 65; Abbreviation: SE is standard error. 
 
Figure 3. Interaction effect anxiety by oxytocin 
Table 3. Moderation Analyses of Anxiety on Placebo Responses of Oxytocin 
 b SE t p R
2 
F p R² 
Model 1     .074 2.47 .093  
Intercept 14.25 5.72 2.49 .016     
Group 17.54 8.17 2.15 .036     
Anxiety 1.19 1.51 .79 .431     
Model 2
 
    .078 1.71 .174 .004 
Intercept 14.51 5.78 2.51 .015     
Group   17.46 8.22 2.12 .038     
Anxiety  .33 2.26 .15 .884     
Group * Anxiety  1.57 3.05 .51 .609     
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The model of stress with interaction term (Table 4; Model 2 and Figure 4) was 
significant (F(3,61) = 5.49, p = .002, R² = .212, R² = .058). This model predicted 21.2% of 
the variance in the sample and predicted 5.8% more variance than the model without 
interaction term. In this model, the interaction between group and stress was significant (b = 
.39, p = .038). Significance of the interaction effect indicates a moderation effect. Table 3 
shows an indication of the direction of the interaction effect. Higher levels of stress result in 
higher levels of oxytocin in the conditioned group in comparison to the control group. The 
main effect of the variable group (Table 4; Model 2) was also significant (b = 17.78, p = 
.022). This was a positive effect, so given that the conditioned group was assigned to number 
1 and the control group was assigned to number 0, participants in the conditioned group had 
higher oxytocin scores than participants in the control group. The main effect of stress was 
not significant (b = .08, p = .520). 
Table 4. Moderation Analyses of Stress on Placebo Responses of Oxytocin 
 b SE T p R
2 
F p R² 
Model 1     .154 5.66 006  
Intercept 14.02 5.46 2.57 .013     
Group 17.83 7.78 2.29 .025     
Stress .24 .09 2.57 .013     
Model 2     .212 5.49 .002 .058 
Intercept 14.42 5.31 2.72 .009     
Group 17.78 7.57 2.35 .022     
Stress .08 .12 .65 .520     
Group * Stress .39 .19 2.12 .038     
Note. N = 65; Abbreviation: SE is standard error. 
 
Figure 4. Interaction effect stress by oxytocin 
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4. Discussion 
The present study was two-aimed. The first aim was to investigate whether it is 
possible to induce a placebo response in oxytocin through the mechanism of classical 
conditioning. Our results demonstrated that it is possible to condition (endogenous) oxytocin 
release. After repeated pairings of oxytocin with the smell of rosewood aroma oil odor in the 
acquisition phase, the aroma oil smell alone triggered a conditioned response in the beginning 
of the evocation phase. Participants showed a conditioned increase of salivary oxytocin levels. 
These results were in line with our hypothesis. Our results were also in line with earlier 
research on the conditioned placebo effect of oxytocin in an animal study. Onaka and Yagi 
(1998) showed that oxytocin can successfully be conditioned in rats. The current study was 
the first study to research the classically conditioned placebo effect of oxytocin in humans. 
Nevertheless, our results were in line with other studies that show supporting results regarding 
the possibility to classically condition hormones in humans. Other hormones that already were 
proven possible to condition are cortisol, growth hormone and insulin (Benedetti et al., 2003; 
Johansen et al., 2003; Sabbioni et al., 1997; Stockhorst et al., 2011; Stockhorst et al., 2004).  
The second aim was to investigate whether anxiety and stress influenced placebo 
responses of oxytocin. The results of the current study showed no effects of anxiety on the 
conditioned placebo effect of oxytocin. Participants who experienced more anxiety did not 
show significantly increased or reduced levels of classically conditioned oxytocin levels 
compared to participants who showed less anxiety. This result was not in line with our 
hypothesis as well as with earlier research. Earlier research found that decreased anxiety was 
associated with increased placebo responses in patients with irritable bowel syndrome (Flaten 
et al., 2011; Vase et al., 2005).  
A possible explanation for our results not being in line with our hypothesis or with 
earlier research could lie in the way of how anxiety is assessed. The study of Vase et al. 
(2005), on which our hypothesis was based, measured anxiety using the Visual Analog Scale. 
Participants were asked: ‘How anxious are you about the pain you may experience during this 
session?’ and rate their anxiety on a scale of 1 (no anxiety) to 10 (the most intense anxiety 
imaginable). It is notable that in this study, anxiety was closely related to the construct of 
negative expectation (Vase et al., 2005). In our research anxiety was assessed using the STAI-
S, with which we measured state anxiety. The STAI-S measured current levels of anxiety by 
rating six statements: ‘I feel calm’, ‘I am tense’, ‘I feel upset’, ‘I am relaxed’, ‘I feel content’, 
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‘I am worried’. Presumably, these questionnaires do not measure the exact same concept of 
anxiety. 
Another difference between the study of Vase et al. (2005) and our study is that 
anxiety levels were measured at two different points in time during the experiment. This way, 
the researchers were able to make within-subjects comparisons with regards to anxiety. 
Whereas, in our study, we only measured anxiety once and made between-subjects 
comparisons with regards to anxiety. Within-subjects designs have greater control over 
individual differences than between-subjects designs and therefore have more statistical 
power. This makes that within-subjects designs are more likely to detect an effect than 
between-subjects designs. Also, in the study of Vase et al. (2005), anxiety was a less 
consistent and a weaker predictor than other predictors in the study (the desire and 
expectation for pain relief). It might be that there is a very small effect of anxiety on placebo 
effects and that our study did not have enough power to detect it.  
Furthermore, in our study, the measures of stress did show an effect on classically 
conditioned placebo responses, but the effect was not in the direction we expected. We 
expected that high stress levels would be associated with low placebo responses. However, 
our results indicated that high stress levels were associated with increased placebo responses. 
These results were in line with earlier research, in the sense that an association of stress with 
placebo responses was found. Although, this association was previously found in the opposite 
direction. Earlier research indicated that decreased stress levels was associated with enhanced 
placebo responses (Benedetti et al., 2006; Flaten et al., 2011). 
A possible explanation of why our results are not in line with our expectations could 
be that people who experience more stress are more sensitive to placebo manipulation. 
Previous research investigating placebo effects in visceroception suggested that psychological 
stress might amplify the placebo effect. In this research 120 participants underwent either the 
Trier Social Stress Test (stressed condition, N = 60) or a simple cognitive task (Control 
condition, N = 60). They were further randomized into groups who either received positive 
(placebo) or neutral verbal suggestions regarding the treatment expectations (intravenous 
administration of saline). Before and after receiving the Trier Social Stress Test or the simple 
cognitive task, participants underwent a visceroception test. They found that the magnitude of 
change in perceived visceral symptoms (urgency) in response to placebo treatment was 
affected by acute psychological stress. For, significant differences in urgency between the 
visceroception tests (before and after) were only found in the stressed condition, not in the 
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control condition (Roderigo et al., 2017). This is corresponding with our results in such a way 
that people who experienced more stress, displayed a stronger placebo effect. 
Another possible explanation for discrepancies in different studies could lie in 
differences in the manner of how stress was included in these studies. In the study of 
Benedetti et al. (2006) physiological stress is induced using proglumide, a substance that 
blocks cholecystokinin receptors. Cholecystokinin is a substance that induces subjective and 
physiological stress, proglumide should inhibit this reaction. In the study of Roderigo et al. 
(2017) psychological stress is induced by applying the Trier Social Stress Test and in our 
study existing psychological stress levels are measured by using the Special Events 
Questionnaire II. Such differences in manners of including stress, for instance differing in 
psychological or physiological stress, could possibly affect or measure different mechanisms 
that may affect the placebo effect in a different way.   
There are several limitations that need to be addressed. The first limitation is regarding 
the generalizability to the general population, as only women who take oral contraceptives 
were included in this study. Enck and Klosterhalfen (2019) argued that gender does play a 
role in the placebo response. They suggest that the mechanisms through which placebo 
responses work are predominantly via conditioning in women and via the manipulation of 
expectancies in men. In our research, the reason for only including women who take 
contraceptives, was that these women show stable oxytocin levels throughout the menstrual 
cycle (Salonia et al., 2005). Future research should not limit the research population in such a 
way, it should include both females and males who do not use medications that regulate the 
hormonal system. This would contribute to our findings by investigating if comparable results 
can be found in a more general research population.  
Also, we did not measure the expectations of participants regarding the treatment they 
received. Expectations are an important underlying mechanism of the placebo effect 
(Benedetti et al., 2005; Benedetti & Piedimonte, 2019; Enck et al., 2008). Although, earlier 
research has shown that expectations presumably do not have an effect on hormonal secretion, 
we cannot rule out the possibility that it influenced our results (Benedetti et al., 2003). For 
instance, expectations might still support the mechanism of classical conditioning (Wager & 
Atlas, 2015). Future research should take the treatment expectations of participants into 
account. 
Another limitation concerns the used measurements for anxiety and stress. When 
measuring anxiety we used the STAI-S, meaning that we measured state anxiety. State 
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anxiety is described as a person’s current level of anxiety. For a more complete view of a 
possible effect of anxiety on the placebo effect of oxytocin, it could be relevant to include trait 
anxiety as well. Trait anxiety entails a person’s general feelings of anxiety (Marteau & 
Bekker, 1992). When measuring stress we used the Special Events Questionnaire II, this 
questionnaire measured if participants had experienced certain life events and it measured 
what the impact of these events was on their lives. So, the level of our measurement of stress 
was dependent on the given life events. For instance, some participants did not experience any 
of these events and were marked as low in stress. While other participants did experience 
several of these life events, their scores of the impact of these events were added up. A 
questionnaire that measures perceived stress regardless of the environment that someone is in 
might be more beneficial for our research question. This could for instance be done by using 
the Perceived Stress Scale by Cohen and colleagues (Cohen, Kamarck, & Mermelstein, 1983; 
Hellhammer, 2010).  
Other limitations are regarding the administration and measurement of oxytocin levels. 
Thus far, we do not exactly know what happens with the exogenously administered oxytocin 
in the human body. For instance, it is unknown how much exogenously administered oxytocin 
reaches the correct part of the brain. It is also unknown whether exogenously administered 
oxytocin interacts with endogenous levels of oxytocin (McCullough, Churchland, & Mendez, 
2013). To investigate mechanisms of the placebo effect of oxytocin it is relevant to know 
what happens with exogenously administered oxytocin.   
 Now we know that oxytocin is a hormone that has the potential to be classically 
conditioned, it can have implications for clinical practice. We know for example that oxytocin 
treatment may have beneficial effects for patients with borderline personality disorder and 
patients witch autism spectrum disorder (Anagnostou et al., 2012; Bertsch et al., 2013). We 
also know that oxytocin treatment might improve glucose homeostasis, increase insulin 
sensitivity and may lead to weight loss in overweight adults (Lawson, 2017). In clinical 
practice, the possibility to classically condition oxytocin might be used in placebo-controlled 
dose reduction. This might have the potential to reduce the dose of the oxytocin in 
pharmacological treatment, while retaining the efficacy of the treatment (Doering & Rief, 
2012). Which could be beneficial in alleviating side effects. Although, according to 
MacDonald et al. (2011), oxytocin treatment with intranasal oxytocin does not yield serious 
side-effects. Another benefit of placebo-controlled dose reduction is the reduction of health 
care costs in pharmacological treatments with oxytocin. Furthermore, the conditioning of 
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oxytocin might have the potential to be useful as a supporting treatment, without increasing 
the medication dose (Kirchhof et al., 2018).   
Future research should investigate the possibilities of placebo-controlled dose 
reduction, as well as the possibilities of conditioned supportive treatments in pharmacological 
treatments with oxytocin. Important to remark is that we should be careful considering these 
possibilities. The reason for this is that the exact implications of real pharmacological 
oxytocin treatments in clinical practice are still unclear. Some studies were unable to find 
(positive) effects of oxytocin treatment (Mameli et al., 2014; Nave, Camerer, & McCullough, 
2015). Findings on the clinical relevance of oxytocin are not yet conclusive and need more 
research to reach consensus. Furthermore, future research could focus on factors that might 
influence classical conditioned placebo responses. Knowledge about such factors might be 
important for clinical practice. It could, for example, be useful in determining which factors 
and to what extend should be present or absent to provide an effective treatment. Our results 
showed that stress might be an influential factor for the conditioned placebo effect of 
oxytocin. However, to make a recommendation for clinical practice, more evidence resulting 
from more thorough research is needed. 
 In conclusion, this study proves that it is possible to induce a placebo effect in 
oxytocin through the mechanism of classical conditioning. In addition, our results indicate 
that some psychological factors may influence the classically conditioned placebo effect of 
oxytocin. In our study, stress had an effect on the conditioned placebo response of oxytocin. 
Increased stress levels were associated with enhanced conditioned placebo responses of 
oxytocin. Anxiety did not have an effect on the conditioned placebo response of oxytocin. 
This may be promising for clinical practice in the future, as making use of the placebo effect 
might be an efficient way to reduce medication dosages and to improve pharmacological 
treatment effects. Herewith, associated factors such as stress, should be taken into account. 
Yet, more research is needed with more substantial evidence to draw more solid conclusions.  
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